Herein, this study comprehensively compares the first-line HAIC plus lenvatinib and PD-(L)1 inhibitors against chemotherapy with or without PD-(L)1 inhibitors for patients with unresectable ICC. The gene discussed is CD274; the disease is intrahepatic cholangiocarcinoma.